However, clinical trials targeting EGFR function have been so far disappointing since the heterogeneous distribution of EGFR throughout the tumor might render cells differentially sensitive towards EGFR inhibition, ultimately leading to therapy failure [51, 69, 70, 83]. This evidence concerns the gene EGFR and neoplasm.